ANI Pharmaceuticals

ANI Pharmaceuticals

Pharmaceuticals
ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

$1.7B

Market Cap • 10/2/2026

2001

(25 years)

Founded

1999

(27 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

4,1

P/S

2,5

P/EBITDA

12,6

P/OCF

12,1

P/FCF

13,2

P/E

56,2

BVPS

22,5

EPS

2

Market Cap

Market Cap

2,1B

EV

2,4B

EV/Revenue

2,9

EV/EBITDA

14,7

EV/EBIT

33,4

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-0,2%

Total Yield

-0,2%

Payout

0%

Retained Earnings

-50,6M

Profitability

Gross Margin

61,1%

EBITDA Margin

19,8%

EBIT Margin

8,7%

Net Margin

4,9%

D&A/EBITDA

56%

R&D/Revenue

6,8%

Capex/Revenue

1,8%

Capex/D&A

16,4%

Capex/OCF

8,8%

SBC/OCF

20,6%

% PPE

4,5%

% Goodwill

4,4%

ROE

8,7%

ROIC

6,3%

Growth

CAGR Revenue 5Y

32,9%

CAGR OCF 5Y

45,9%

Leverage

N.D./EBITDA

2,1

Debt/Equity

0%

Current Ratio

2,6

Quick Ratio

1,9

Interest Coverage

332,1%

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium